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Background
The benefits of endoscopic testing for colorectal-cancer screening are uncertain. We 
evaluated the effect of screening with flexible sigmoidoscopy on colorectal-cancer 
incidence and mortality.
Methods
From 1993 through 2001, we randomly assigned 154,900 men and women 55 to 74 
years of age either to screening with flexible sigmoidoscopy, with a repeat screening 
at 3 or 5 years, or to usual care. Cases of colorectal cancer and deaths from the disease 
were ascertained.
Results
Of the 77,445 participants randomly assigned to screening (intervention group), 83.5% 
underwent baseline flexible sigmoidoscopy and 54.0% were screened at 3 or 5 years. 
The incidence of colorectal cancer after a median follow-up of 11.9 years was 11.9 
cases per 10,000 person-years in the intervention group (1012 cases), as compared 
with 15.2 cases per 10,000 person-years in the usual-care group (1287 cases), which 
represents a 21% reduction (relative risk, 0.79; 95% confidence interval [CI], 0.72 to 
0.85; P<0.001). Significant reductions were observed in the incidence of both distal 
colorectal cancer (479 cases in the intervention group vs. 669 cases in the usual-care 
group; relative risk, 0.71; 95% CI, 0.64 to 0.80; P<0.001) and proximal colorectal can-
cer (512 cases vs. 595 cases; relative risk, 0.86; 95% CI, 0.76 to 0.97; P = 0.01). There 
were 2.9 deaths from colorectal cancer per 10,000 person-years in the intervention 
group (252 deaths), as compared with 3.9 per 10,000 person-years in the usual-care 
group (341 deaths), which represents a 26% reduction (relative risk, 0.74; 95% CI, 
0.63 to 0.87; P<0.001). Mortality from distal colorectal cancer was reduced by 50% 
(87 deaths in the intervention group vs. 175 in the usual-care group; relative risk, 0.50; 
95% CI, 0.38 to 0.64; P<0.001); mortality from proximal colorectal cancer was unaf-
fected (143 and 147 deaths, respectively; relative risk, 0.97; 95% CI, 0.77 to 1.22; P = 0.81).
Conclusions
Screening with flexible sigmoidoscopy was associated with a significant decrease in 
colorectal-cancer incidence (in both the distal and proximal colon) and mortality 
(distal colon only). (Funded by the National Cancer Institute; PLCO ClinicalTrials.gov 
number, NCT00002540.)
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Colorectal cancer is the second leading cause of cancer-related deaths in the United States.1 Colorectal-cancer mor-
tality2-4 and incidence5,6 are reduced with screen-
ing by means of fecal occult-blood testing. Endo-
scopic screening with flexible sigmoidoscopy or 
colonoscopy is more sensitive than fecal testing for 
the detection of adenomatous polyps, the precursor 
lesions of colorectal cancer.7-9 Three European 
randomized trials of flexible sigmoidoscopy have 
been performed.10 In the United Kingdom, one-
time screening with flexible sigmoidoscopy signifi-
cantly reduced the incidence of colorectal cancer 
(by 23%) and associated mortality (by 31%).11 In 
Italy, an 18% reduction in incidence and a non-
significant 22% reduction in mortality were ob-
served,12 whereas in Norway, no benefit was ob-
served after 7 years of follow-up.13
In the United States, the multicenter, ran-
domized Prostate, Lung, Colorectal, and Ovarian 
(PLCO) Cancer Screening Trial evaluated flexible 
sigmoidoscopy in comparison with usual care. Two 
screenings with flexible sigmoidoscopy were of-
fered, 3 or 5 years apart. Previous reports have 
described the outcome from the first screening10 
and the yield from both screenings.14 We report 
here on the effect of screening flexible sigmoid-
oscopy on the incidence of distal and proximal 
colorectal cancer and related mortality.
Methods
Study Design
A total of 154,900 men and women 55 to 74 years 
of age were enrolled from 1993 through 2001; they 
provided written informed consent and completed 
baseline questionnaires. The primary exclusion cri-
teria were a history of prostate, lung, colorectal, or 
ovarian cancer; ongoing treatment for any type of 
cancer except basal-cell or squamous-cell skin 
cancer; and, beginning in 1995, assessment by 
means of a lower endoscopic procedure (flexible 
sigmoidoscopy, colonoscopy, or barium enema ex-
amination) in the previous 3 years. Further details, 
including data on recruitment through mass mail-
ing, have been reported previously.15,16 Randomiza-
tion was performed in blocks stratified according 
to screening center, age, and sex. The study was 
sponsored by the National Cancer Institute. All the 
authors vouch for the accuracy of the data and the 
fidelity of the study to the protocol. The protocol 
and statistical analysis plan are available with the 
full text of this article at NEJM.org.
Participants in the intervention group were 
offered flexible sigmoidoscopy at baseline and at 
3 years (for those who underwent randomization 
before April 1995) or at 5 years. Repeat screening 
in persons who received a diagnosis of colorectal 
cancer or adenoma after the initial screening was 
discouraged but did occur14 (see Fig. S1 in the 
Supplementary Appendix, available at NEJM.org). 
Physicians and nurse examiners followed stan-
dardized procedures for flexible sigmoidoscopic 
examinations. An examination was considered to 
be positive if a polyp or mass was detected. Bi-
opsies were not routinely performed. Participants 
were referred to their primary care physicians for 
decisions regarding diagnostic follow-up. Medical 
records related to follow-up, a diagnosis of cancer, 
and cancer complications were collected.
Death from colorectal cancer was the primary 
end point. Secondary end points included colorec-
tal-cancer incidence, cancer stage, survival, harms 
of screening, and all-cause mortality. All cancers 
and deaths were ascertained primarily by means of 
a mailed Annual Study Update questionnaire. Par-
ticipants who did not return questionnaires were 
contacted by repeat mailing or telephone. Cancer 
incidence, stage, and location were verified from 
medical records.17 Information on vital status was 
supplemented by periodic linkage to the National 
Death Index. Deaths that were potentially related 
to prostate, lung, colorectal, or ovarian cancer were 
reviewed in a blinded fashion, in an end-point 
adjudication process.18 Colorectal-cancer deaths 
included deaths due to colorectal cancer and those 
due to its treatment. Carcinoid tumors were in-
cluded as colorectal-cancer cases. Cancers located 
in the rectum through the splenic flexure were 
defined as distal, and those in the transverse 
colon through the cecum were defined as proxi-
mal. A screening-detected cancer was defined as 
a colorectal cancer diagnosed within 1 year after a 
positive flexible sigmoidoscopic examination.
Assessment of Study-Group Contamination
Colorectal screening with flexible sigmoidoscopy 
or colonoscopy outside the study protocol, per-
formed for routine care (contamination), was as-
sessed with the use of biennially and, later, annu-
ally administered health-status questionnaires. In 
total, 13,788 randomly selected participants (10,077 
in the usual-care group and 3711 in the interven-
tion group) were included in the analysis. Verifica-
tion of reported procedures was not obtained. To 
estimate contamination in the usual-care group 
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during the screening phase (study years 0 through 
5), we determined the proportion of participants at 
study years 5 and 6 who reported having undergone 
routine endoscopic testing in the previous 5 years. 
Contamination by colonoscopy in the intervention 
group during the screening phase was defined as 
routine colonoscopy in participants without a posi-
tive flexible sigmoidoscopic examination and was 
estimated from reports on colonoscopy in a sub-
group of 1392 participants in the intervention 
group.19,20 To estimate use of colonoscopy after the 
screening phase, we determined the proportion of 
participants in each group in study years 11 through 
13 who reported having undergone routine colono-
scopic testing in the previous 5 years.
Statistical Analysis
The primary analysis was an intention-to-screen 
comparison of colorectal-cancer mortality between 
the study groups. Event rates were defined as the 
number of events (cancers or deaths) divided by 
person-years. For mortality, person-years were 
measured from randomization to the date of death 
or the date of last follow-up (censoring date), and 
for incidence, person-years were measured from 
randomization to the date of diagnosis, death, or 
censoring, whichever came first. Data were cen-
sored on December 31, 2009, or at 13 years from 
randomization, whichever came first.
The trial was designed to have 90% power to 
detect a 15% or greater relative reduction in 
colorectal-cancer mortality in the intervention 
group, as compared with the usual-care group, on 
the assumption of at least 85% compliance with 
screening in the intervention group and no more 
than 15% contamination among participants in 
the usual-care group.15
We calculated the pointwise confidence inter-
vals for incidence-rate and mortality ratios assum-
ing a Poisson distribution for the number of events 
and, through asymptotic methods, a normal distri-
bution for the logarithm of the ratio.21 The num-
ber needed to invite for screening to prevent one 
colorectal-cancer death or case was defined as the 
number of intervention-group participants divided 
by the difference in colorectal-cancer deaths or 
cases between groups. The adjusted, sequential 
P value and confidence interval for the colorectal-
cancer mortality ratio were derived in accordance 
with the sequential design and the weighted 
method used to monitor the trial, which allows for 
a varying rate ratio.22 An interim analysis plan was 
used to monitor the primary end point for effi-
cacy and futility. We assessed the between-group 
difference in mortality with the use of a weighted 
log-rank test, incorporating increasing weights 
that were proportional to the pooled mortality. 
The weighted statistic was chosen because of the 
presumed delay in the effect of screening on 
colorectal-cancer mortality. The monitoring design 
stipulated a one-sided efficacy boundary, con-
structed by means of the Lan–DeMets procedure 
with an O’Brien–Fleming spending function,23 and 
a nonbinding futility boundary was constructed 
with the use of stochastic curtailment24 (see the 
Supplementary Appendix). All analyses were per-
formed with SAS/STAT software, version 9 (SAS 
Institute),25 or R software, version 2.12.0 (R Devel-
opment Core Team).26
Results
Characteristics of the Participants and Use 
of Screening
A total of 77,445 participants were randomly as-
signed to flexible sigmoidoscopy, and 77,455 to 
usual care. The baseline characteristics of the par-
ticipants were similar in the two study groups (Ta-
ble 1); the median follow-up time was 11.9 years, 
and the mean follow-up time was 11.0 years. Vital 
status within a year after the data-cutoff date was 
known for 99.9% of participants, and compliance 
with the Annual Study Update questionnaire was 
93.8%. Randomization and follow-up are shown 
in Figure S1 in the Supplementary Appendix.
In the intervention group, 83.5% of the partici-
pants (64,653) underwent baseline screening and 
54.0% (41,858) underwent subsequent screening. A 
total of 86.6% of participants (67,071) underwent 
at least one flexible sigmoidoscopic screening, and 
50.9% (39,440) underwent two screenings; in 
28.5% of participants (22,083), at least one screen-
ing was positive for a polyp or mass. Of partici-
pants with abnormal screening results, 80.5% un-
derwent a diagnostic intervention within 1 year, 
95.6% of whom underwent colonoscopy; the rate 
of colonoscopy performed as a direct effect of 
screening with flexible sigmoidoscopy was 21.9%.
Colorectal-Cancer Incidence and Mortality 
According to Study Group
Table 2 shows colorectal-cancer incidence and mor-
tality in the intervention group as compared with 
the usual-care group. The incidence of colorectal 
cancer was 11.9 cases per 10,000 person-years in 
the intervention group (1012 cases), as compared 
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with 15.2 cases per 10,000 person-years in the 
usual-care group (1287 cases), which represents a 
21% reduction (relative risk, 0.79; 95% confidence 
interval [CI], 0.72 to 0.85; P<0.001). Significant 
reductions were observed in the incidence of both 
distal colorectal cancer (479 cases in the interven-
tion group vs. 669 cases in the usual-care group; 
relative risk, 0.71; 95% CI, 0.64 to 0.80; P<0.001) 
and proximal colorectal cancer (512 cases vs. 595 
cases; relative risk, 0.86; 95% CI, 0.76 to 0.97; 
P = 0.01). The relative risk of colorectal cancer 
among men was 0.73 (95% CI, 0.66 to 0.82) and 
among women 0.86 (95% CI, 0.76 to 0.98), with a 
borderline significant interaction between sex and 
study-group assignment (P = 0.052). The reduction 
in the incidence of colorectal cancer was similar 
for participants 55 to 64 years of age (518 cases 
vs. 662 cases; relative risk, 0.78; 95% CI, 0.69 to 
0.87) and for those 65 to 74 years of age (494 cases 
vs. 625 cases, relative risk, 0.79; 95% CI, 0.71 to 
Table 1. Characteristics of the Study Participants.*
Characteristic




no. of participants (%)
Sex
Female 39,105 (50.5) 39,111 (50.5)
Male 38,340 (49.5) 38,344 (49.5)
Age
55–59 yr 25,851 (33.4) 25,839 (33.4)
60–64 yr 23,783 (30.7) 23,771 (30.7)
65–69 yr 17,457 (22.5) 17,473 (22.6)
70–74 yr 10,354 (13.4) 10,372 (13.4)
Race or ethnic group†
White (non-Hispanic) 66,874 (86.4) 65,708 (84.8)
Black (non-Hispanic) 3,883 (5.0) 3,825 (4.9)
Hispanic 1,421 (1.8) 1,397 (1.8)
Asian 2,791 (3.6) 2,785 (3.6)
Other or unknown 2,476 (3.2) 3,740 (4.8)
Educational level
High-school graduate or less 22,892 (29.6) 22,583 (29.2)
Some college 25,935 (33.5) 25,585 (33.0)
College graduate 26,659 (34.4) 25,915 (33.5)
Unknown 1,959 (2.5) 3,372 (4.4)
Prior FOBT‡
Yes 29,244 (37.8) 29,890 (38.6)§
No 43,858 (56.6) 42,223 (54.5)
Unknown 4,343 (5.6) 5,342 (6.9)
Prior lower GI endoscopy¶
Yes 9,736 (12.6) 10,113 (13.1)§
No 64,653 (83.5) 62,997 (81.3)
Unknown 3,056 (3.9) 4,345 (5.6)
Either prior FOBT or prior lower GI endoscopy
Yes 31,511 (40.7) 31,990 (41.3)§
No 40,648 (52.5) 39,161 (50.6)
Unknown 5,286 (6.8) 6,304 (8.1)
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0.89). The number needed to invite for screening in 
order to prevent 1 case of colorectal cancer was 
282 (95% CI, 210 to 427).
Mortality related to colorectal cancer was 2.9 
per 10,000 person-years in the intervention group 
(252 deaths), as compared with 3.9 per 10,000 
person-years in the usual-care group (341 deaths), 
which represents a 26% reduction (relative risk, 
0.74; 95% CI, 0.63 to 0.87; P<0.001). Mortality 
related to distal colorectal cancer was reduced by 
50% (87 deaths in the intervention group vs. 175 
in the usual-care group; relative risk, 0.50; 95% 
CI, 0.38 to 0.64; P<0.001), but mortality related 
to proximal colorectal cancer (143 vs. 147 deaths, 
respectively; relative risk, 0.97; 95% CI, 0.77 to 
1.22; P = 0.81) was unaffected. Men had a 34% 
reduction in colorectal cancer mortality (139 vs. 
211 deaths; relative risk, 0.66; 95% CI, 0.53 to 
0.81) and women a 13% reduction (113 vs. 130 
deaths; relative risk, 0.87; 95% CI, 0.68 to 1.12); 
the interaction between sex and study-group as-
signment was not significant (P = 0.10). The relative 
risks for colorectal-cancer mortality among par-
ticipants 55 to 64 years of age and 65 to 74 years 
of age were 0.84 (95% CI, 0.67 to 1.06) and 0.65 
(95% CI, 0.52 to 0.82), respectively (P = 0.11 for the 
interaction between age and study-group assign-
ment). The number needed to invite for screening 
in order to prevent 1 colorectal-cancer death was 
871 (95% CI, 567 to 1874).
The cumulative incidences of overall and distal 
colorectal cancer were higher in the intervention 
group through approximately 3 years, after which 
cumulative incidences became lower in the inter-
vention group (Fig. 1A and 1C). The cumulative 
incidences of proximal colorectal cancer (Fig. 1E) 
were similar for the first few years but became and 
remained lower after year 3 in the intervention 
group. Overall colorectal-cancer mortality and 
mortality related to distal and to proximal colorec-
tal cancer are shown in Figure 1B, 1D, and 1F. 
Between-group differences in mortality emerged 
within a few years and persist for total and dis-
tal colorectal cancer, but no difference in mor-








no. of participants (%)
First-degree relative with colorectal cancer
Yes 7,643 (9.9) 7,322 (9.5)
No 65,299 (84.3) 64,506 (83.3)
Unknown 4,503 (5.8) 5,627 (7.3)
Daily use of aspirin or ibuprofen in past 12 mo
Yes 24,822 (32.1) 23,949 (30.9)‖
No 50,368 (65.0) 49,766 (64.3)
Unknown 2,255 (2.9) 3,740 (4.8)
Aspirin or ibuprofen use ≥3–4 times per wk in past 12 mo
Yes 33,248 (42.9) 32,087 (41.4)**
No 41,971 (54.2) 41,658 (53.8)
Unknown 2,226 (2.9) 3,710 (4.8)
*  There were no significant differences between the groups except as noted. FOBT denotes fecal occult-blood test, and 
GI gastrointestinal.
†  Race or ethnic group was determined by self-report.
‡  Prior FOBT indicates a test within 3 years before study entry.
§  P<0.001
¶  Prior lower GI endoscopy indicates sigmoidoscopy, colonoscopy, or barium enema examination within 3 years before 
randomization.
‖  P = 0.03
** P = 0.01
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Incidence and Stage of Cancer According to 
Means of Detection
Table 3 shows colorectal-cancer incidence and stage 
according to the means of detection. Screening-
detected cancers accounted for 24.1% of colorectal 
cancers (244 of 1012) in the intervention group. 
Among participants with screening-detected can-
cers, 82.8% of the cancers were distal, whereas 
among participants who were never screened, 
52.8% were distal, and among participants with 
cancers not detected by screening, 31.6% were dis-
tal (P<0.001). Participants with screening-detected 
cancers were more likely to have early-stage cancer 
(stage I or II) than participants who were never 
screened or those whose tumors were not detected 
by screening (75.4% vs. 50.9% and 50.7%, respec-
tively; P<0.001 for both comparisons).
Incidence and Mortality According to 
Location and Stage of Cancer
Table 4 shows colorectal-cancer incidence and mor-
tality according to the location in the colon and the 
stage at diagnosis. Case fatality rates for stage I, II, 
III, and IV cancers were similar in the intervention 
and usual-care groups and were approximately 6%, 
11%, 30%, and 79%, respectively. There was a re-
duction in the incidence of distal colorectal cancer 
in the intervention group for each cancer stage, 
ranging from 19.8% for stage I cancers (50 fewer 
cases) to 61.7% for stage IV cancers (66 fewer cas-







(95% CI) P Value
no. of  
participants
rate per 10,000  
person-yr  
(95% CI)
no. of  
participants




All colorectal cancers 1012 11.9 (11.2–12.7) 1287 15.2 (14.4–16.0) 0.79 (0.72–0.85) <0.001
Location of cancer†
Distal 479 5.6 (5.1–6.2) 669 7.9 (7.3–8.5) 0.71 (0.64–0.80) <0.001
Proximal 512 6.0 (5.5–6.6) 595 7.0 (6.5–7.6) 0.86 (0.76–0.97) 0.01
Sex
Male 567 13.6 (12.4–14.7) 768 18.5 (17.2–19.9) 0.73 (0.66–0.82) <0.001
Female 445 10.3 (9.4–11.3) 519 12.0 (11.0–13.0) 0.86 (0.76–0.98) 0.02
Age at randomization
55–64 yr 518 9.4 (8.6–10.2) 662 12.1 (11.2–13.0) 0.78 (0.69–0.87) <0.001
65–74 yr 494 16.6 (15.1–18.1) 625 20.9 (19.3–22.5) 0.79 (0.71–0.89) <0.001
Mortality
All colorectal-cancer deaths 252 2.9 (2.5–3.2) 341 3.9 (3.5–4.3) 0.74 (0.63–0.87) <0.001
Location of cancer†
Distal 87 1.0 (0.8–1.2) 175 2.0 (1.7–2.3) 0.50 (0.38–0.64) <0.001
Proximal 143 1.6 (1.4–1.9) 147 1.7 (1.4–2.0) 0.97 (0.77–1.22) 0.81
Sex
Male 139 3.2 (2.7–3.8) 211 4.9 (4.3–5.6) 0.66 (0.53–0.81) <0.001
Female 113 2.6 (2.1–3.0) 130 2.9 (2.4–3.4) 0.87 (0.68–1.12) 0.28
Age at randomization
55–64 yr 133 2.4 (2.0–2.8) 157 2.8 (2.3–3.2) 0.84 (0.67–1.06) 0.16
65–74 yr 119 3.9 (3.2–4.6) 184 6.0 (5.1–6.9) 0.65 (0.52–0.82) <0.001
* The median follow-up time for incidence was 11.9 years (interquartile range, 10.2 to 13.0) and for mortality was 12.1 years (interquartile 
range, 10.4 to 13.0).
† Distal location was defined as the rectum through the splenic flexure, and proximal as the transverse colon through the cecum. For inci-
dence, the location was unknown for 21 cases in the flexible-sigmoidoscopy group and 23 cases in the usual-care group. For mortality, the 
location was unknown for 22 deaths in the flexible-sigmoidoscopy group and 19 deaths in the usual-care group.
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Figure 1. Overall, Distal, and Proximal Colorectal-Cancer Incidence and Mortality.
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es). Mortality related to distal colorectal cancer was 
also reduced for each stage, by 21.4% for stage I 
cancers (3 fewer deaths) to 60.7% for stage IV can-
cers (51 fewer deaths). The incidence of cancer in 
the proximal colon was reduced by 14.4 to 20.7% 
in the intervention group for stage I, II, and III 
cancers (22, 34, and 25 fewer cases, respectively) 
but by only 2.0% (2 fewer cases) for stage IV dis-
ease. The number of deaths from proximal colorec-
tal cancer was similar in the two groups. Overall, 
there were only 4 fewer deaths from proximal 
colorectal cancer in the intervention group. Because 
of the relative paucity of cancers in the descending 
colon and splenic flexure (Table S2 in the Supple-
mentary Appendix), limiting the definition of 
distal cancer to cancers in the rectum and sig-
moid had little effect on the incidence or mortal-
ity results.
Cancer Treatment, Screening Complications 
and False Positive Results, and Deaths  
from Other Causes
The rates of administered treatment for colorec-
tal cancer with surgery, chemotherapy, or radia-
tion therapy were similar overall and according to 
cancer stage in the two groups (Table S1 in the 
Supplementary Appendix).
There were 3 bowel perforations, 2 by the same 
operator, in 107,236 flexible sigmoidoscopic ex-
aminations (2.8 per 100,000). Among participants 
with a positive flexible sigmoidoscopic examina-
tion and no cancer detected on follow-up, there 
were 19 perforations during 17,672 subsequent 
diagnostic or therapeutic colonoscopic examina-
tions (107.5 per 100,000). False positive results of 
sigmoidoscopy, with no neoplasia identified at 
subsequent diagnostic testing, were observed 













yr 3 or 5 total no. (%) number (percent)
All colorectal  
cancers
192 52 244 (100.0) 607 (100.0) 161 (100.0) 1012 (100.0) 1287 (100.0)
Location
Distal 165 37 202 (82.8) 192 (31.6) 85 (52.8) 479 (47.3) 669 (52.0)
Proximal 26 15 41 (16.8) 403 (66.4) 68 (42.2) 512 (50.6) 595 (46.2)
Unknown 1 0 1 (0.4) 12 (2.0) 8 (5.0) 21 (2.1) 23 (1.8)
Sex
Male 136 33 169 (69.3) 324 (53.4) 74 (46.0) 567 (56.0) 768 (59.7)
Female 56 19 75 (30.7) 283 (46.6) 87 (54.0) 445 (44.0) 519 (40.3)
Stage
I 113 33 146 (59.8) 148 (24.4) 40 (24.8) 334 (33.0) 407 (31.6)
II 31 7 38 (15.6) 160 (26.4) 42 (26.1) 240 (23.7) 309 (24.0)
III 24 6 30 (12.3) 168 (27.7) 43 (26.7) 241 (23.8) 328 (25.5)
IV 5 3 8 (3.3) 107 (17.6) 25 (15.5) 140 (13.8) 209 (16.2)
Carcinoid 17 3 20 (8.2) 10 (1.6) 2 (1.2) 32 (3.2) 9 (0.7)
Unknown 2 0 2 (0.8) 14 (2.3) 9 (5.6) 25 (2.5) 25 (1.9)
* This category includes participants who underwent at least one screening flexible sigmoidoscopic examination and who had cancers that 
were detected because of symptoms, detected by screening performed outside the study protocol, or detected more than 1 year after a posi-
tive screening examination.
† This category includes participants who did not undergo a screening flexible sigmoidoscopic examination and who had cancers that were 
detected because of symptoms or detected by screening performed outside the study protocol.
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among 20% of men and 13% of women.27 Some of 
the false positive sigmoidoscopic examinations 
may have been due to false negative results of colo-
noscopy. Deaths from other causes, excluding 
prostate, lung, colorectal, and ovarian cancers, 
totaled 9138 (11.8%) in the intervention group and 
9286 (12.0%) in the usual-care group (relative risk, 
0.98; 95% CI, 0.96 to 1.01; P = 0.28) (Table S3 in 
the Supplementary Appendix).
Endoscopic Contamination
The estimated rate of endoscopic contamination in 
the usual-care group during the screening phase 
was 25.8% (95% CI, 23.6 to 28.0) for flexible sig-
moidoscopy, 34.4% (95% CI, 32.0 to 36.8) for colo-
noscopy, and 46.5% (95% CI, 43.9 to 49.1) for either 
flexible sigmoidoscopy or colonoscopy. The rate of 
colonoscopy in the intervention group during the 
screening phase by participants without a positive 
screening examination was 5.5% (95% CI, 4.5 to 
6.5). The rate of routine colonoscopy after the 
screening phase was 47.7% (95% CI, 44.7 to 50.7) in 
the intervention group and 48.0% (95% CI, 45.2 to 
50.8) in the usual-care group.
Discussion
In this randomized study, flexible sigmoidoscopy, 
as compared with usual care, was associated with 
a 26% reduction in overall colorectal-cancer mor-
tality and a 21% reduction in the incidence of 
colorectal cancer. Mortality related to distal colorec-
tal cancer was reduced by 50%, and the incidence 
was reduced by 29%. A significant 14% reduction in 
Table 4. Colorectal-Cancer Incidence and Mortality According to Location and Stage.
Variable Cancer Stage Total
I II III IV Carcinoid Unknown
Flexible-sigmoidoscopy group
Cases of colorectal cancer — no. 334 240 241 140 32 25 1012
Deaths from colorectal cancer — no. (%) 20 (6.0) 26 (10.8) 70 (29.0) 113 (80.7) 3 (9.4) 20 (80.0) 252 (24.9)
Cases of distal colorectal cancer — no. 202 110 96 41 24 6 479
Deaths from distal colorectal cancer — no. (%) 11 (5.4) 15 (13.6) 28 (29.2) 33 (80.5) 0 0 87 (18.2)
Cases of proximal colorectal cancer — no. 131 130 145 96 8 2 512
Deaths from proximal colorectal cancer — no. (%) 9 (6.9) 11 (8.5) 42 (29.0) 78 (81.2) 3 (37.5) 0 143 (27.9)
Usual-care group
Cases of colorectal cancer — no. 407 309 328 209 9 25 1287
Deaths from colorectal cancer — no. (%) 21 (5.2) 33 (10.7) 102 (31.1) 163 (78.0) 4 (44.4) 18 (72.0) 341 (26.5)
Cases of distal colorectal cancer — no. 252 144 157 107 3 6 669
Deaths from distal colorectal cancer — no. (%) 14 (5.6) 25 (17.4) 50 (31.8) 84 (78.5) 1 (33.3) 1 (16.7) 175 (26.2)
Cases of proximal colorectal cancer — no. 153 164 170 98 6 4 595
Deaths from proximal colorectal cancer — no. (%) 7 (4.6) 8 (4.9) 52 (30.6) 77 (78.6) 3 (50.0) 0 147 (24.7)
Between-group differences*
Distal colorectal cancer
Cases — no. (% reduction in incidence) 50 (19.8) 34 (23.6) 61 (38.9) 66 (61.7) −21 (−700.0) 0 190
Deaths — no. (% reduction in mortality) 3 (21.4) 10 (40.0) 22 (44.0) 51 (60.7) 1 (100.0) 1 (100.0) 88
Proximal colorectal cancer
Cases — no. (% reduction in incidence) 22 (14.4) 34 (20.7) 25 (14.7) 2 (2.0) −2 (−33.3) 2 (50.0) 83
Deaths — no. (% reduction in mortality) −2 (−28.6) −3 (−37.5) 10 (19.2) −1 (−1.3) 0 0 4
* Differences in cases and deaths were calculated as the number in the usual-care group minus the number in the flexible-sigmoidoscopy 
group. The percentage difference was calculated as 100 − [(flexible-sigmoidoscopy rate ÷ usual-care rate) × 100]. The flexible-sigmoidoscopy 
rate was defined as cases in the flexible-sigmoidoscopy group divided by the flexible-sigmoidoscopy population, and the usual-care rate as 
cases in the usual-care group divided by the usual-care population.
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the incidence of proximal colorectal cancer was ob-
served, but there was no significant reduction in 
mortality related to proximal cancer. The baseline 
characteristics, rate and time of follow-up, treat-
ment, and deaths according to cancer stage were 
similar in the two study groups, findings that sug-
gest similarities in the underlying risk, biologic fea-
tures of the cancers, and treatment outcome. These 
results provide strong support for the observed ben-
efit as being directly attributable to sigmoidoscopic 
screening.
The observed reductions in incidence and mor-
tality are similar to the results of the United King-
dom11 and Italian12 studies of flexible sigmoidos-
copy. Although the end results of these trials are 
similar, there are notable differences among the 
studies in enrollment criteria, compliance, screen-
ing frequency, and the use of endoscopic screening 
outside the protocol. In the United Kingdom study, 
a single flexible sigmoidoscopic screening for par-
ticipants 55 to 64 years of age was performed. In 
the PLCO trial, two screenings were offered, and 
participants ranged from 55 to 74 years of age. In 
the United Kingdom study, 71.2% of participants 
underwent a screening examination, whereas in 
the PLCO trial, 86.6% underwent at least one 
screening. In the PLCO trial, the second screen-
ing increased the cumulative diagnostic yield of 
cancer or advanced adenoma by 26% among 
women and 34% among men.14 However, we can-
not measure the incremental benefit of the second 
examination on colorectal-cancer incidence or 
mortality.
In the United States, endoscopic screening has 
been widely endorsed,28,29 and population-based 
data show an increase in use.30 We identified sub-
stantial use of flexible sigmoidoscopy and colonos-
copy in the usual-care group during the time that 
the intervention group was undergoing screening 
and in both groups during follow-up after screen-
ing. This testing probably reduced the difference in 
mortality and incidence between the two groups. 
However, screening in the PLCO trial was per-
formed primarily in the first study year, when 
83.5% of participants were screened, whereas in 
the usual-care group, testing accumulated over 
time. In conjunction with the European trials,11,12 
our study confirms that flexible sigmoidoscopy 
substantially reduces colorectal-cancer incidence 
and mortality, especially with regard to distal 
colorectal cancer.
Observational studies have raised doubts about 
the benefit of endoscopic screening in reducing 
mortality31,32 from and the incidence33,34 of proxi-
mal colorectal cancer. There is a lesser degree of 
protection against cancer in the proximal colon 
than in the distal colon.31-36 In the United King-
dom trial of flexible sigmoidoscopy, the benefit 
with regard to colorectal-cancer incidence and 
mortality was limited to the distal colon, but 
only 5% of participants underwent colonosco-
py.11 In the Italian study, 8.4% of participants 
were referred for colonoscopy,12 and the reduc-
tions in the incidence of proximal colorectal 
cancer (9%) and related mortality (15%) were not 
significant. In the PLCO trial, we found a signifi-
cant reduction in the incidence of proximal colorec-
tal cancer. This effect was achieved with a colonos-
copy rate of 21.9% as a direct effect of abnormal 
screening results of f lexible sigmoidoscopy, in 
addition to colonoscopy occurring outside the 
screening protocol and after the screening pe-
riod. We did not observe a reduction in mortal-
ity related to proximal colorectal cancer. Much 
of the benefit in reducing colorectal-cancer mor-
tality from screening derives from a reduction in 
stage IV disease,4 which has a much higher mor-
tality than lower stages. In the PLCO trial, 79.1% 
of participants with stage IV disease died of 
colorectal cancer. For cancers in the distal co-
lon, reductions of more than 60% in the inci-
dence of stage IV disease and related mortality 
were observed. In contrast, for cancers in the 
proximal colon, no significant reductions in the 
incidence of stage IV disease or related mortality 
were identified. Furthermore, in the intervention 
group, tumors that were not detected by screen-
ing were more likely to be proximal and at a 
later stage than screening-detected tumors (Ta-
ble 3).37
As compared with the distal colon, the proxi-
mal colon poses a more difficult challenge for 
colorectal-cancer control because of limitations 
in bowel preparation, a greater prevalence of ad-
vanced serrated adenomas, which are harder to 
detect than conventional adenomas,38,39 and bio-
logic differences, including a greater incidence of 
BRAF mutation,39 microsatellite instability,38,40 
and CpG island methylator phenotype (CIMP).40 
Although our protocol was associated with a 
reduction in the incidence of proximal colorectal 
cancer, presumably because of the detection and 
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removal of precursor adenomas that would oth-
erwise have progressed to cancer, it apparently 
did not succeed in identifying and successfully 
removing a proportionally greater number of 
precursor lesions destined to develop into fatal 
colorectal cancers. We have estimated that using 
colonoscopy rather than flexible sigmoidoscopy 
as the screening method in the PLCO trial would 
have increased the number of screening-detected 
cancers by approximately 16 percentage points 
(from <25% to approximately 40% of colorectal 
cancers diagnosed in participants assigned to 
flexible sigmoidoscopy) and that two thirds of 
that increase would have been attributable to in-
creased detection of proximal colorectal can-
cer.37 The effect on the incidence of proximal 
colorectal cancer and related mortality of the 
additional polyp removal with universal colonos-
copy is not known.
The effectiveness of flexible sigmoidoscopy in 
reducing mortality related to distal colorectal can-
cer reflects the reduction in cancer incidence, or 
the reduced number of tumors that could have 
resulted in death, and the identification of earlier-
stage tumors, which are less likely to cause 
death than later-stage tumors. Screening-detected 
cancers, though accounting for less than 25% of 
tumors in the intervention group, were distinctly 
and predominantly at an early stage (Table 3).37
Although the trial was not powered to detect 
the effect of sigmoidoscopic screening on colorec-
tal-cancer mortality and incidence in subgroups, 
the results are suggestive of a stronger effect 
among men than among women. This finding 
may be due to the fact that women had a lower 
proportion of screening-detected cancers (Table 3) 
and a higher proportion of proximal colorectal 
cancers than men.37 A significant differential ef-
fect between the screening of participants 55 to 
64 years of age and those 65 to 74 years of age 
was not observed.
Our results can be compared with those of the 
Minnesota trial of fecal occult-blood testing. Af-
ter 13 years of follow-up, with six rounds of fecal 
occult-blood testing and a 38% rate of colonoscopy 
in the annually screened group, colorectal-cancer 
incidence was reduced by 12% (a nonsignificant 
difference) and mortality by 33% (a significant 
difference).41 In the PLCO trial, after a median 
follow-up of 11.9 years with up to two flexible 
sigmoidoscopic screenings in addition to screen-
ings outside the protocol in both groups, incidence 
was reduced by 21% and mortality by 26%. En-
doscopic testing appears to have a more potent 
protective effect than fecal occult-blood testing in 
reducing the incidence of colorectal cancer and 
requires fewer rounds of testing, presumably be-
cause endoscopic testing detects more precursor 
adenomas.7-9 However, whether endoscopic eval-
uation is a better screening test depends on the 
population and available resources.
In conclusion, screening with flexible sigmoid-
oscopy, in conjunction with colonoscopy (pre-
dominantly) for diagnosis and management after 
abnormal test results, was associated with a 
significant and clinically important decrease in 
colorectal-cancer incidence and mortality. The inci-
dence of colorectal cancer was reduced in both 
the distal and proximal colon. A significant reduc-
tion in mortality was observed only for cancer in 
the distal colon.
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